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Modulation of intracellular protein–protein interactions has been – and remains – a
challenging goal for the discovery and development of small-molecule therapeutic agents.
Progress in the pharmacological targeting and understanding at the molecular level of one
such interaction that is relevant to cancer drug research, viz. that between the tumour
suppressor protein p53 and its negative regulator HDM2, is reviewed here. The ﬁrst X-ray
crystal structure of a complex between a small peptide from the trans-activation domain of
p53 and the N-terminal domain of HDM2 was reported almost 10 years ago. The nature of
this interaction, which involves just three residue side chains in the p53 peptide ligand and a
compact hydrophobic binding pocket in the HDM2 receptor, together with the attractive
concept of reactivating the anti-proliferative functions of p53 in tumour cells, has spurned a
great deal of eﬀort aimed at ﬁnding drug-like antagonists of this interaction. A variety of
approaches, including both structure-guided peptidomimetic and de novo design, as well as
high through-put screening campaigns, have provided a wealth of leads that might be turned
into actual drugs. There is still some way to go as far as optimisation and preclinical
development of such leads is concerned, but it is clear already now that antagonists of the p53–
HDM2 protein–protein interaction have a good chance of ultimately being successful in
providing a new anti-cancer therapy modality, both in monotherapy and to potentiate the
eﬀectiveness of existing chemotherapies.
KEY WORDS: Cancer; oncology; protein–protein interaction; drug discovery; structure-based design;
peptidomimetics; p53; MDM2; HDM2; p53–HDM2 inhibitors.
INTRODUCTION
Despite the fact that there are currently several
polypeptide drugs in clinical use – and many more
under development (Gadek and Nicholas, 2003) – the
main thrust of drug discovery is still aimed at small-
molecule agents, because these are generally more
favourable in terms of biopharmaceutical properties,
especially absorption, disposition, stability to
metabolism, and lack of immunogenicity. Therapeu-
tic polypeptides such as insulin, erythropoietin,
humanised antibodies – to name just a few – all target
cell surface receptors. However, most promising drug
targets are actually found within – rather than on the
external surface or outside – of the cells that make up
diseased tissues. These intracellular targets cannot be
addressed eﬀectively with polypeptide agents that are
generally incapable of traversing biological mem-
branes. For the same reason such compounds cannot
Abbreviations: Non-standard abbreviations are deﬁned at the ﬁrst
occurrence. Amino acid and peptide nomenclature conforms to
IUPAC-IUB guidelines [Eur. J. Biochem., 138 (1984) 9].
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parenterally.
There is a long and successful history of the dis-
covery and development of small-molecule agents
against intracellular targets, especially enzymes and
other receptors or proteins that naturally bind small
ligands. The drawback here is that it has been noto-
riously diﬃcult to ﬁnd suﬃciently potent drug-like
leads and drug candidates that exert their pharma-
cological activity as a result of attenuating other
target classes, particularly protein–protein interac-
tions (PPIs). Nevertheless, drug modulation of PPIs
is a highly desirable strategy, since it holds much
promise, not only because there are presumably many
more PPIs than enzyme and classical small-molecule
receptor targets, but also in terms of speciﬁcity and
selectivity of drug action. Unlike e.g. enzymes, which
fall into groups of closely related members with
highly conserved ligand-binding motifs (e.g. the ATP-
binding pocket in protein kinases), PPIs are struc-
turally more diverse and individual PPIs are therefore
comparatively unique.
The main perceived diﬃculty in targeting PPIs
with small molecules concerns the size and shape of
the interfaces between associating proteins. The
buried surface area in PPIs is typically much larger
than the solvent-accessible surface area of even the
largest potential inhibitor molecules that are still
suﬃciently membrane-permeable. Furthermore, PPIs
tend to be shallower than enzyme active sites and it is
therefore conceptually diﬃcult to ﬁnd shape-com-
plementary small inhibitor molecules that can exclude
suﬃcient water of hydration from a protein surface to
form strong hydrophobic interactions, a prerequisite
for aﬃnity. New concepts are emerging, however,
that suggest that the situation is not completely
hopeless. It is now believed that most of the binding
energy of PPIs is localised to so-called hot spots,
involving just a few amino acid residues in either
binding partner (Bogan and Thorn, 1998). These hot
spots are not unlike enzyme active sites and might be
able to be addressed with drug-like small molecules.
Pioneer studies show that this can indeed be the case
for certain PPIs (reviewed in Fischer, 2005). Impor-
tantly, blocking a hot spot with a small molecule can
be suﬃcient to prevent formation of the much larger
overall PPI. Exploitation of adventitious allosteric
sites, present in individual members of protein con-
formational ensembles, is another powerful new
concept in PPI inhibitor design (Arkin and Wells,
2004). In this approach small-molecule binding sites
are targeted that may not have any natural ligands or
physiological signiﬁcance. If the conformational state
of the target protein that is stabilised in this manner
does not associate with the partner protein, then an
indirect way of blocking a PPI has been achieved.
The need for new disease-associated targets and
new therapeutic strategies is nowhere more important
than in oncology, where the medical need is urgent
and where drug approval productivity has dipped
alarmingly over the last few years (Lengauer et al.,
2005). Traditional cancer treatments rely heavily on
chemotherapeutic agents that target the mechanics of
DNA replication. The use of such drugs is limited by
the side eﬀects emanating from toxicity to normal
proliferating cells. More recently, strategies have been
adopted where deregulated components of the signal
transduction pathways of cancer cells are targeted,
especially protein kinases (Dancey and Sausville,
2003). A few of these agents are now in clinical
use, but the validity and overall eﬀectiveness of these
newer treatment modalities remain to be established.
For this reason alternative strategies are of interest.
PPIs are especially important in the cellular processes
that govern oncogene and tumour suppressor func-
tions in general, as well as regulation and deregula-
tion of the cell proliferation cycle and the cell death
machinery (Oltersdorf et al., 2005). PPI antagonists
are therefore of tremendous potential as a molecular
strategy for the discovery of new cancer drugs. Here
I shall review progress to date on the most advanced
PPI drug target in oncology: the interaction between
the tumour suppressor protein p53 and its negative
regulator, the human double minute-2 (HDM2)
oncogene. Several recent reviews on the topic of the
p53–HDM2 interaction have been presented (Chene,
2003; Zheleva et al., 2003; Chene, 2004; Fischer and
Lane, 2004; Lane and Fischer, 2004; Sunder-Plass-
mann and Giannis, 2004; Buolamwini et al., 2005;
Fotouhi and Graves, 2005); here I shall put emphasis
on the most recent work.
THE INTERACTION BETWEEN p53
AND HDM2: TARGET RATIONALE
The p53 protein integrates cellular stress signals
and functions as a transcription factor with many
target genes whose transcripts are involved in DNA
repair, cell cycle arrest, and activation of the apop-
totic programme. So central is p53 to the life and
death decisions of every cell that its functions are
ablated in practically all malignant cells (Lane, 2001).
This can happen in diﬀerent ways: typically through
4 Fischerdirect loss-of-function mutation in the p53 gene in
about half of all tumours, or indirectly, frequently by
ampliﬁcation or over-expression of the HDM2 gene
(Momand et al., 1998). HDM2 encodes a 491-amino
acid residues polypeptide that contains a p53-binding
domain, an acidic region, as well as zinc- and ring-
ﬁnger domains. HDM2 is a p53-speciﬁc ubiquitin E3
ligase and thus promotes the proteasomal degrada-
tion of p53. Furthermore, it binds to the N-terminal
transactivation domain of p53 and therefore blocks
the latter’s transcriptional activity. A third mecha-
nism by which HDM2 regulates p53 activity is by
promoting the latter’s nuclear export. HDM2 con-
tains a signal sequence that is similar to nuclear
export signals of various viral proteins. When bound
to HDM2, p53 is thus deactivated by removal from
the nucleus, the site of transcription factor activity
(Tao and Levine, 1999). There exists a negative
feedback loop between HDM2 and p53: following
genotoxic stress to normal cells, the ability of p53 to
bind to HDM2 is blocked through various post-
translational regulatory modiﬁcations, thereby pre-
venting HDM2-mediated inactivation and degrada-
tion of p53. Consequently, p53 levels rise, causing cell
cycle arrest or apoptosis. Over-expression of HDM2
is therefore an eﬃcient way that tumour cells use to
prevent accumulation and activation of p53.
It follows that reactivation of p53 in tumours is an
attractive therapeutic strategy. Depending on whether
or not p53 is functional in a tumour, various strategies
can be proposed (Zheleva et al., 2003). If p53 is non-
functional, e.g. reintroduction of p53 through gene
therapy or pharmacological rescue of mutant p53
could be envisaged (Foster et al., 1999). On the other
hand, if p53 is functional in the tumour cells, then
inhibiting the ubiquitin ligase activity of HDM2, or
blocking the interaction between p53 and HDM2,
should be viable. Progress has recently been made in
the discovery of HDM2 ligase inhibitors (Lai et al.,
2002; Yang et al., 2005) and other ways of interfering
with p53-speciﬁc HDM2 functions (Issaeva et al.,
2004), but here we shall conﬁne our in-depth discus-
sion to inhibition of the p53–HDM2 PPI.
An important question for any new cancer ther-
apy strategy is that of therapeutic margin, i.e. will a
drug against the new target be able to distinguish
between malignant and normally proliferating cells?
It could be argued that attenuation of HDM2 might
result in promiscuous toxicity on the basis that
MDM2 (mouse double minute 2) knock-out mice are
not viable (Montes de Oca Luna et al., 1995). How-
ever, gene knock-out is not the same as pharmaco-
logical inhibition of the corresponding gene product.
Thus mice with a hypomorphic MDM2 allele pro-
duce only about 30% of the normal levels of MDM2.
Such mice are viable, however, suggesting that
attenuation of HDM2 in normal tissues is by no
means invariably lethal (Mendrysa et al., 2003).
There are clearly important diﬀerences between the
p53 response in normal versus tumour cells. In nor-
mal cells HDM2 levels do not depend on the tran-
scriptional activity of p53, whereas they do in cancer
cells. Additionally, in normal cells another tumour
suppressor protein, p14
Arf, does not control HDM2,
whereas in tumour cells p14
Arf is involved in the
negative regulation of HDM2. One can therefore
expect that cancer cells with functional p53 should be
selectively sensitive to blockade of the p53–HDM2
interaction, and reacquire the ability to die through
p53-mediated apoptosis (O’Leary et al., 2004). The
inherent safety of p53 reactivation in cancer cells is
implied by several ﬁndings, e.g. the recent approval of
the ﬁrst gene therapy in China based on adenoviral
delivery of p53 (Surendran, 2004). Furthermore,
in vivo studies using HDM2 gene silencing mediated
by antisense oligonucleotides, show selective and
eﬃcacious anti-tumour eﬀects (Zhang et al., 2005).
Radiotherapy and most current forms of chemo-
therapy, which damage DNA, also induce the p53
response. The negative regulation of p53 by HDM2
limits the extent of p53 activation and therefore the
therapeutic eﬀectiveness of DNA-damaging agents. If
the HDM2 feedback inhibition of p53 is interrupted,
an increase in functional p53 levels should augment
the therapeutic eﬀectiveness of such agents by
restoring p53 functions that lead to apoptosis, or by
reversing p53-associated drug resistance. Again this
expectation has been borne out by studies with
HDM2-targeted antisense oligonucleotides, which
have been observed to potentiate the eﬀects of both
radio and chemotherapy in vitro and in vivo (Bianco
et al., 2005).
STRUCTURAL CHARACTERISATION
OF THE p53–HDM2 INTERACTION
The region of HDM2 that binds to p53 was
originally narrowed down to residues 19–102,
whereas the minimal HDM2-binding domain of p53
was identiﬁed as a 15 residue sequence (amino acids
15–29) from the transactivation domain. It was
realised that the transactivation and HDM2-binding
sites of p53-must overlap, since e.g. residues F19 and
Antagonists of the p53–HDM2 Interaction 5W23 were important in both respects. An X-ray
crystal structure of the complex between HDM2 and
the 15-residue transactivation domain peptide of p53
(Kussie et al., 1996) showed that HDM2 possesses a
deep hydrophobic cleft into which the p53 peptide
binds as an amphipathic a-helix (Fig. 1). Residues
F19, W23, and L26 of p53 insert deeply into a com-
pact binding pocket composed of 14 conserved
hydrophobic and aromatic amino acids that make
multiple van-der-Waals contacts to p53. The p53–
HDM2 interface buries a total of 1498 A ˚ 2 of surface
area (690 A ˚ 2 thereof in HDM2), most of which is
hydrophobic. There are only two intermolecular
hydrogen bonds: one between the F19 backbone
amide of p53 and the Q72 side chain of HDM2 at the
entrance of the cleft, the other between the p53 W23
indole NH and the HDM2 L54 backbone carbonyl
deep inside the cleft. Consistent with p53 peptide
structure–activity relationships (SARs) and protein
mutagenesis studies, the p53–HDM2 interaction is
dominated by only three residues in p53: F19, W23,
and L26, which together bury no more than about
500 A ˚ 2 of surface area. The p53-binding site of
HDM2 thus possesses all the hallmarks of a PPI hot
spot (Bogan and Thorn, 1998).
The HDM2-binding site on p53 was mapped with
the aid of overlapping synthetic peptides and the
minimal sequence was found to be
18TFSDLW
23
(Picksley et al., 1994). Although longer peptides
encompassing this sequence were potent inhibitors of
p53–HDM2 complex formation, the 18–23 hexapep-
tide itself had little aﬃnity, presumably due to
conformational ﬂexibility (Bo ¨ ttger et al., 1997).
Screening of phage-displayed peptide libraries also
revealed sequences containing the HDM2 binding
motif (Bo ¨ ttger et al., 1996). Here the starting
12mer peptide MPRFMDYWEGLN had sub-mic-
romolar aﬃnity and was 28-fold more potent than
the corresponding wild-type p53-derived peptide
16QETFSDLWKLLF
27. Substitution and truncation
studies revealed that the 8mer peptide FMDYWEGL
was the minimal active sequence retaining micromo-
lar aﬃnity for HDM2. Based on the known binding
mode of the corresponding p53 sequence (Fig. 1), the
helical structure of this peptide was stabilised by
introduction of the a,a-disubstituted amino acid
residues a-aminoisobutyric acid (Aib) and 1-amino-
cyclopropanecarboxylic acid (Ac3c) in place of the
Asp and Gly residues, respectively. Molecular mod-
elling suggested proximity of the Tyr side chain to the
-amino group of the HDM2 K94 residue and a
phosphonomethylphenylalanine (Pmp) residue was
used to replace Tyr. The resulting peptide was about
7-fold more potent, suggesting that the hypothetical
stabilising salt bridge between the phosphonate and
amino groups was in fact operating. Finally, inspec-
tion of the binding pocket for W23 showed incom-
plete occupancy, suggesting substituents at the indole
6-position would improve binding. This was the case
and substantial potency gain was obtained. Thus
starting with the wild-type p53 12mer sequence,
aﬃnity was increased by >1700-fold and the
optimised peptide (Fig. 2) inhibited full-length p53
binding to GST-HDM2 with an IC50 of 5 nM
Fig. 1. The X-ray crystal structure complex between a p53 peptide (residues 17–29; green CPK sticks and ribbon indicating secondary
structure) and HDM2 (grey CPK surface). The three main p53 residue side chains (F19, W23, and L26) involved in the interaction are shown
with solid sticks. Hydrogen bonds are indicated by dashed yellow lines (left). The p53-binding hot spot is illustrated on the right, where the
three p53 residues are shown as a space-ﬁlled model, with the HDM2 surface as a mesh. Constructed from PDB # 1YCR. 3D structural
illustrations were created using the programme PyMOL (DeLano, W.L. The PyMOL Molecular Graphics System (2002) DeLano Scientiﬁc,
San Carlos, CA, USA. http://www.pymol.org).
6 Fischer(Garcı´a-Echeverrı´a et al., 2000). Interestingly, this
peptide was found to possess cellular activity, pre-
sumably due to its high solubility and extremely high
aﬃnity, and despite poor permeability (even lipo-
philic peptides rarely show high membrane perme-
ability). The peptide was capable of inducing p53
activation and apoptosis selectively in HDM2-over-
expressing cancer cells in vitro (Che ` ne et al., 2000,
2002).
The p53–HDM2 interaction has also been studied
by NMR (Stoll et al., 2000; Schon et al., 2002, 2004;
McCoy et al., 2003; Fry et al., 2004). Overall the
HDM2 N-terminal domain constructs that have
been used to date in structural studies are compara-
tively ﬂexible and their solution conformations are
stabilised upon ligand binding. The ﬁrst experimental
NMR structure of uncomplexed HDM2 has recently
been determined (Uhrinova et al., 2005). This struc-
ture is interesting because it sheds light on the likely
conformational changes in HDM2 upon p53 binding.
It had previously been suggested that the N-terminal
15 or 20 residues of HDM2 occupy the hydrophobic
p53-binding cleft in the apo-form (McCoy et al.,
2003; Liu et al., 2004; Yin et al., 2005a). It thus
appeared that the N-terminus of HDM2 forms an
intramolecular lid, which is opened upon p53 bind-
ing. The apo-HDM2 structure partially conﬁrms this
picture: a part of the N-terminus of HDM2 does
indeed occupy one side of the p53-binding site, and
major conformational changes in HDM2 upon ligand
binding are thus likely (Fig. 3).
PEPTIDOMIMETIC INHIBITORS
b-Peptides
Peptides composed of b-amino acids, i.e. homo-
logues of natural a-amino acids containing an addi-
tional backbone CH2 group, are of great interest
because of their conformational versatility and in vivo
stability compared to natural peptides (Seebach and
Matthews, 1997; Seebach et al., 1998b; Cheng et al.,
2001). Depending on the substitution patterns at C2
(b
2) and C3 (b
3)o fb-amino acid residues in
b-peptides, the latter take up a host of diﬀerent
helical and sheet-like conformations (Cheng et al.,
2001). Of particular importance are peptides com-
Fig. 2. An optimised p53-derived peptide inhibitor of the p53–
HDM2 interaction.
Fig. 3. An ensemble of 23 NMR solution structures of HDM2 (Uhrinova et al., 2005), illustrating the ﬂexibility of the termini (left).
A comparison between the p53 peptide-bound HDM2 structure (HDM2 yellow, p53 green) and a representative NMR apo-HDM2 con-
formation (blue) reveals that overall the two are very similar but that the former displays a more open p53-binding cleft (right). Furthermore,
in the apo structure a part of the N-terminus (residues 18–24; blue CPK sticks) occupies part of the p53-binding cleft taken up by the p53
residues 27–29 (green CPK sticks) in the complex structure. Constructed from PDB # 1YCR & 1Z1M.
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3-amino acids, because these can readily be
obtained by various synthetic methods, including
homologation of natural a-amino acids (Juaristi,
1997; Seebach et al., 1998a). Depending on the
stereochemistry of the b-amino acids, either a left-
handed or a right-handed 14-helix is formed. Peptides
consisting of b
3-amino acids that are derived from
naturally occurring L-amino acids adopt left-handed
14-helices. The 14-helix is stabilised by hydrogen
bonds between backbone amides at position i and
carbonyls at i+2, forming a series of intercatenated
14-membered rings (Cheng et al., 2001). Whereas the
a-helix has a 3.6-residue repeat, the 14-helix repeats
approximately every 3 residues, which positions the
side chains of every third residue along one of three
faces of the helix. It was shown that the 14-helix,
which in many cases is not very stable in water, can
be stabilised with oppositely charged residues posi-
tioned to form intramolecular salt bridges between
residues at the i and i+3 positions along one or two
of the three helical faces (Hart et al., 2003).
Such 14-helical b
3-peptides have now been used as
a peptidomimetic scaﬀold for the three p53 residue
side chains that are responsible for the interaction
with HDM2 (Kritzer et al., 2004). As discussed
above, naturally these three residues are found on one
face of an a-helix at positions i, i+4, and i+7.
It turns our that this geometry is very similar in a
b
3-peptide containing the corresponding b
3-residues
at positions i, i+3, and i+6 (Kritzer et al., 2005).
Peptides of the form 1 (Fig. 4) were prepared and
studied in a competitive binding assay based on
ﬂuorescence polarisation (Lai et al., 2000; Knight
et al., 2002). Only the variant where b
3-Xaa, b
3-Yaa,
and b
3-Zaa corresponded to b
3-Leu, b
3-Trp, and b
3-
Phe, respectively, was found to inhibit the p53–
HDM2 interaction selectively, with an IC50 of about
100 lM, i.e. with an aﬃnity that was about 2.5-fold
lower than the native p53(15–31) peptide (Kritzer
et al., 2004).
Oligomers of b-proline, i.e. (S)-pyrrolidine-3-
carboxylic acid, and related cyclic b-amino acids,
have also been suggested as potential scaﬀolds for
p53 mimetics (Zhong and Carlson, 2005), and gen-
erally as a good choice for a short helical scaﬀold
(Huck et al., 2003; Sandvoss and Carlson, 2003).
Speciﬁcally, compound 2 (Fig. 4) was designed based
on known HDM2 inhibitors; as far as can be ascer-
tained this compound has not actually been syn-
thesised and tested, however (Zhong and Carlson,
2005).
As with many polypeptide and peptidomimetic
compounds, membrane permeability is a problem
and the appeal of the b
3-peptide strategy as a thera-
peutic approach towards p53–HDM2 inhibition may
therefore be limited. It should be noted, however,
that several vectors are known that can be conjugated
with impermeable eﬀector molecules to eﬀect delivery
into cells (Fischer et al., 2001). These delivery vectors
are peptides themselves and therefore still limited in
terms of physiological stability and thus in vivo use.
It turns out, however, that such delivery peptides
can also be 7mimicked by b
3-peptide analogues
(Umezawa et al., 2002). It might therefore be possible
Fig. 4. Macrodipole-stabilised 14-helical b
3-peptides 1 as p53–HDM2 antagonists. Diﬀerent combinations of the F19, W23, and L26 side
chains were introduced at the positions b
3-Xaa, b
3-Yaa, and b
3-Zaa. The best solution was Leu, Trp, and Phe at Xaa, Yaa, and Zaa,
respectively (see text). A model of this peptide, assuming an ideal 14-helical structure, was build (dark sticks; only interacting side chains
shown) and overlaid with the known interaction of a p53 peptide (only key side chains shown as light sticks) with HDM2 (surface). The
residue preceding b
3-Leu clashes with the H96 imidazole, although it can easily be imagined that the H96 side chain moves to allow access.
Constructed from PDB # 1YCR. A hypothetical peptidomimetic of the p53 peptide residue triad based on a b-Pro oligomer (2) has also been
proposed.
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3-peptidic p53–HDM2 inhibitors
for in vivo use.
b-Hairpin Peptidomimetics
The b-turn is a structural motif that is frequently
used by proteins to display localised groups of amino
acid residues for recognition of partner proteins (Ball
et al., 1993) and b-hairpin mimetics of the b-turn,
including e.g. cyclic peptides incorporating the L-Pro–
D-Pro dipeptide unit, have been designed as scaﬀolds
for the synthesis of conformationally constrained
peptides and peptidomimetics (Favre et al., 1999;
Jiang et al., 2000; Descours et al., 2002; Robinson
et al., 2005). The distance between the C
a atoms of
F19 and W23 on one face of the HDM2-bound p53
a-helix happens to be close to the distance expected
between the C
a atoms of two residues (i and i+2)
along one strand of a b-hairpin. The three key p53
residues were therefore mounted on a b-hairpin core
in order to mimic the natural spatial arrangement
(Fasan et al., 2004). An initial lead compound (3a in
Fig. 5) was thus obtained. However, this showed only
modest inhibitory activity (IC50=125 lM) in a
biosensor assay that employed a streptavidin-immo-
bilised biotinylated p53 peptide (residues 15–29). The
HDM2 protein used (residues 17–126) bound to the
p53 peptide–sensor surface with a Kd value of
670 nM. Lead optimisation aﬀorded peptide 3b, with
almost 1000-fold higher aﬃnity (IC50=140 nM).
Based on NMR studies it seemed likely that the weak
inhibitory activity of 3a was due to the absence of a
stable b-hairpin solution conformation. Peptide SAR
studies revealed that the introduction of aromatic
side chains (R
4 &R
5 side chains in 3) stabilised the
hairpin conformation and enhanced binding to
HDM2. Furthermore, introduction of a 6-chloro
group in the Trp indole ring (R
2 in 3b) further
increased potency, analogously to what had been
observed earlier in the context of linear peptides
(Garcı´a-Echeverrı´a et al., 2000). The complex crystal
structure between HDM2 and peptide 3b (Fig. 5)
illustrates that the side chain of 6-Cl-Trp penetrates
deeply into the core of HDM2 and brings the chlorine
atom into close contact with the aromatic side chain
of F86.
Chlorofusin
This new fungal metabolite was discovered as a
result of a screening programme that involved testing
over 53,000 microbial extracts for the presence of
inhibitors of the binding of p53 to HDM2 (Duncan
et al., 2001). The structure of chlorofusin was
subsequently elucidated (Duncan et al., 2001, 2002;
Desai et al., 2003; Malkinson et al., 2003): it consists
of a 9-residue cyclic peptide that contains both
common and unusual L- and D-amino acids; the Orn
side chain amino group forms part of a highly func-
tionalised tricyclic chromophore (Fig. 6). It was
demonstrated by surface plasmon resonance that
chlorofusin binds the N-terminal domain of HDM2
containing residues 1–126, with a Kd of 4.7 lM
(Duncan et al., 2003). Because chlorofusin analogues
Fig. 5. b-Hairpin mimetics of a-helical p53 peptides (left; SC indicates side chain). The X-ray crystal structure of the inhibitor 3b–HDM2
17-125
complex at 1.4 A ˚ resolution is shown on the right. The Phe, 6-Cl-Trp, and Leu residues of the peptidomimetic are depicted as sticks, the
remainder as a secondary structure cartoon only; the corresponding p53 peptide residue side chains (alignment with PDB # 1YCR) are shown
as light sticks, and the HDM2 surface is depicted as a mesh. Constructed from a structure co-ordinate ﬁle kindly provided by Prof. J.A.
Robinson (University of Zu ¨ rich) ahead of publication.
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HDM2 interaction (Desai et al., 2003; Malkinson
et al., 2003), it is likely that the chromophore, which
contains novel fused 1-oxa-6-aza-spiro[4.5]dec-7-en-
10-ol and butyric acid 3-chloro-1-methyl-2,6-dioxo-
cyclohex-3-enyl ester systems, is involved directly
in the recognition of HDM2, perhaps at the p53
F19-W23-L26 site. Apart from the facts that the
chromophore is essential for biological activity and
that the stereochemistry of the D-Ade-8 residue is
important for overall conformation, no SARs are
known at present (Desai et al., 2003; Malkinson et al.,
2003).
Terphenyls
Terphenyls exhibit low-energy structures in which
the phenyl rings adopt staggered conformations
where substituents (e.g. R
1 and R
2 in 4; Fig. 7)
approximate the position and angular orientation of
amino acid residues on one face of an a-helix (Orner
et al., 2001). Because a-helical secondary structures
play an important role in the way that non-contiguous
amino acid residue side chains are displayed for PPI
hot spots, non-peptidic scaﬀolds that mimic this
structural motif have wide potential application in
drug design (Yin and Hamilton, 2005). In fact dif-
ferent terphenyl derivatives have been designed
successfully as inhibitors of PPIs where helical con-
formations are important in one of the interacting
partners. Examples include pro-apoptotic antagonists
of the BCL-xL–Bak BH3 domain (Yin et al., 2005b)
and inhibitors of HIV gp41 assembly and viral fusion
(Ernst et al., 2002).
This concept has now also been applied for
the design of peptidomimetics of the three key p53
residues implicated in HDM2-binding (Chen et al.,
2005; Yin et al., 2005a). A ﬂuorescence polarisation
competition assay (Kritzer et al., 2004) with a
labelled p53 peptide (C-terminal Cys-ﬂuorescein
15SQETFSDLWKLLPENNV
31; Kd=233 nM) was
used to determine the binding aﬃnities of the ter-
phenyl derivatives to HDM2 (residues 21–188).
Compounds with a bismethylated central phenyl, e.g.
Fig. 6. A plausible modelled solution conformation [based on
structural studies (Duncan et al., 2001, Malkinson et al., 2003)] of
chlorofusin is depicted. Amino acids are labelled, including
the 2-aminodecanoyl (Ade) and ornithine (Orn) residues. The side
chain of the latter bears the chromophore unit, whose absolute
stereochemistry is still unknown.
Fig. 7. Substituted terphenyls 4 and 5 mimic the a-helical i, i+4, and i+7 side-chain arrangement found for the F19, W23, and L26 p53
residues (dark sticks and ribbon) in the HDM2-bound conformation. A likely conformation of terphenyl 5b (light sticks) was modelled and
aligned with the three p53 residue side chains (PDB # 1YCR).
10 Fischer4a and 4b (Fig. 7) showed Ki values of around 2–
3 lM. Analogues with aromatic substituents on the
central ring were more potent, e.g. for the benzyl and
methylnaphth-2-yl congeners 5a and 5b, Ki values of
ca. 1 lM and 0.2 lM, respectively, were recorded.
Clearly the naphthyl side chain is a comparatively
close mimic of the Trp indole system.
The HDM2 binding surface of the terphenyl
compounds was mapped using
15N-HSQC NMR
experiments. E.g. compound 5b induced chemical
shift changes at residues V28, F55, L57, G58, V93,
and K94, which, with the exception of V28, line the
p53 binding pocket. Similar chemical shift changes
were observed in the binding of the p53 peptide to
HDM2 (Schon et al., 2004). It therefore seems highly
likely that active terphenyls recognise the same
HDM2 site as p53.
At present nothing is known about the cellular
eﬀects and mode of action for the potent terphenyls
5. Analysis of the earlier compounds 4, on the other
hand, has been presented (Chen et al., 2005). These
induce nuclear p53 accumulation and transcriptional
activation in cell culture at 15–40 lM. Furthermore,
anti-proliferative eﬀects were observed in the colon
carcinoma cell line HCT116, which harbours wild-
type p53, but not in a derivative cell line with targeted
deletion of p53 (Bunz et al., 1998).
Tryptophan-Based Peptidomimetics
The ﬁrst comparatively small peptidomimetic
p53–HDM2 antagonists to be reported were N
a-acyl-
tryptophanyl-piperazides from AstraZeneca (Luke
et al., 1999). These compounds were discovered using
a combination of structure-based design and combi-
natorial chemistry. Compound 6 (Fig. 8), e.g., had a
potency of 4 lM in a competitive p53 binding assay
(Luke et al., 2000). A related approach has been
adopted more recently by workers at Schering–
Plough, who developed indole-substituted N
a-(2-
phenoxybenzoyl)tryptophan derivatives, again in a
combined design and library synthesis and deconvo-
lution strategy (Zhang et al., 2004). Here a high
trough-put assay was developed and applied. This
was based on ﬂuorescence polarisation anisotropy and
used the 2-nM Kd peptide Ac-Phe-Arg-Dpr(ﬂuor-
ophore)-Ac6c-(6-Br-Trp)-Glu-Glu-Leu-NH2 (where
the ﬂuorophore was 6-carboxyﬂuorescein; Dpr, 2,3-
diaminopropionic acid; Ac6c, a-aminocyclohexyl
carboxylic acid) and HDM2(17–125). A library of (2-
phenoxybenzoyl)tryptophan-based HDM2 inhibitors
was synthesised and tested in order to explore the
SARs of C5/C6/N1 substitutions. The phenoxy
moiety was intended to mimic the p53 F19 side chain
and the C5/C6-substituted Trp residues were used to
mimic W23. The N1 substitutions were intended to
target the adjacent p53 L26 pocket in HDM2. Several
compounds with low micromolar to sub-micromolar
potency were found, e.g. for compounds 7a, 7b, and
7c (Fig. 8) Ki values of 0.4, 0.1, and 0.6 lM were
measured, respectively.
SMALL MOLECULE INHIBITORS
Chalcones
Chalcones have long been known as ﬂavonoid
precursor compounds with anti-proliferative proper-
ties emanating from various biological activities,
including disruption of the cell cycle, inhibition of
angiogenesis, mitochondrial uncoupling, or induction
of apoptosis (Go et al., 2005). Certain chalcones were
also found to interfere with the p53–MDM2 inter-
action (Stoll et al., 2001). Using a two-site ELISA
assay based on a biotinylated p53-derived peptide
with the sequence MPRFMDYWEDL (Bo ¨ ttger
et al., 1996), chalcone carboxylic acids 8a–8d (Fig. 9)
were shown to be inhibitors with mid-micromolar
potency. Furthermore, an electrophoretic gel mobil-
ity shift assay (Bo ¨ ttger et al., 1997) was used to
ascertain the ability of test compounds to restore
DNA binding of full-length tetrameric p53 following
release from the complex with HDM2. Compounds
that were active in the competitive binding ELISA
had some eﬀect but only compound 8c completely
resolved the super-shift induced by HDM2-binding
Fig. 8. Acyltryptophanylpiperazides and indole-substituted N
a-
(2-phenoxybenzoyl)tryptophan peptidomimetic p53–HDM2
inhibitors.
Antagonists of the p53–HDM2 Interaction 11and released active p53. NMR using a recombinant
HDM2(1–118) fragment was also used to verify
binding aﬃnities and binding modes of the active
chalcones (Stoll et al., 2000, 2001). The Kd derived for
e.g. chalcone 8d was 250 lM (244 lM by ELISA).
The NMR shift perturbation pattern observed sug-
gested that this compound – and other active chal-
cones – recognised the p53 binding site (Fig. 9), but
in a diﬀerent way to the natural ligand. The chloro-
phenyl group of 8d binds somewhat less deeply than
the p53 W23 indole into the Trp sub-pocket, whereas
the F19 and L23 sub-sites are not occupied by 8d.
Instead, the anisole ring stacks against F55 (pertur-
bations were also observed at the neighbouring Y56)
of HDM2, which brings the carboxylate group into
proximity with the K51 side chain amino group. In
the p53–HDM2 complex crystal structure (Kussie et
al., 1996) the side chain amino group of K51 forms a
salt bridge with E25; possibly this salt bridge is bro-
ken upon binding of 8d and a new bridge is formed
between the chalcone carboxylate and K51.
No cellular activity was discussed in the original
report of the p53 antagonist chalcone carboxylic
acids (Stoll et al., 2001). Compounds with carbox-
ylic acid functions that are ionised at physiological
pH often display poor membrane permeability.
It was subsequently suggested that corresponding
boronic acid chalcones remain unionised at physio-
logical pH and that they would be capable of
forming more favourable interactions with the side
chain amino group of K51 in HDM2 (Kumar et al.,
2003). However, a comparison between e.g.
carboxylic acid 8c and boronic acids 8e and 8f in
terms of anti-proliferative potency against a range of
breast cancer cell lines, did not reveal an appreciable
diﬀerence in potency (Kumar et al., 2003). Because
no biochemical potency data for the boronic acid
derivatives has been reported, this result is diﬃcult
to interpret. However, both in the phenyl 8 and
pyrrole 9 series (e.g. 9a versus 9b), cytotoxic activity
did not apparently depend on the presence of the
boronate function. Subsequently it was reported that
the cellular mode of action of boronic acid chal-
cones is consistent with inhibition of the p53–
HDM2 complex. Both apoptosis analysis and
colony formation assays of p53-isogenic cell lines
showed that the p53
+/+ cells were more sensitive to
the active boronic chalcones than the p53
)/)cancer
cells (Modzelewska et al., 2004).
Aryl Sulphonamides
A virtual screening approach was taken by
workers at Cyclacel for the identiﬁcation of p53–
HDM2 inhibitors (Wang et al., 2004; Zheleva et al.,
2004). A high through-put docking programme
known as LIDAEUS (Wu et al., 2003) was employed
in an in silico screen of small-molecule databases,
conﬁgured from the co-ordinates of the known p53–
HDM2 complex X-ray crystal structure (Kussie et al.,
1996). Proposed hits included phenyl thienylsulfo-
nates such as 10 (Fig. 10) and structurally related
extended phenyl thienylsulfonamides 11. Veriﬁcation
of hits was accomplished using a competitive binding
assay between HDM2 and a ﬂuorescently labelled
Fig. 9. Chalcones 8 and the related pyrrole derivatives 9 inhibit the p53–HDM2 interaction. The modelled binding mode of 8d [based on
NMR studies (Stoll et al., 2001)] into the structure of the p53–HDM2 complex (PDB # 1YCR) is shown on the right. The HDM2 surface is
shown in light grey, with the exception of the labelled residues K51, E52, and F55 & Y56; the p53 peptide is shown as a ribbon with the F19,
W23, and L26 side chains as sticks; chalcone 8d is shown as a stick model.
12 Fischerp53 peptide (Bo ¨ ttger et al., 1996), similar to the assay
used by the 3D Pharmaceuticals/J&J group as
described below. Lead optimisation was aimed at
designing out the potential physiological reactivity of
the 2-chloro-3-nitro-thiophene system present in 10,
as well as potency optimisation. The former objective
was accomplished with analogues such as 12,a n d
potency gains were achieved by introduction of a
third aryl group on the sulphonamide N, e.g. com-
pound 13, with target-consistent cellular activity at
low micromolar potency.
The arylsulfonamide p53–HDM2 antagonists
were found signiﬁcantly to induce p53 transcriptional
activity, as measured in a luciferase-based p53
reporter gene assay, and the p21
WAF1 gene product,
which is transcriptionally regulated by p53, was
induced in cancer cells treated with lead compounds.
Furthermore, these compounds potently and
selectively killed cancer cells through induction of
apoptosis. Interestingly, the eﬀects of the compounds
were not limited to cells containing wild-type p53,
suggesting that there is another target of HDM2 that
is aﬀected. It is known that the regulation of the E2F-
1 transcription factor involves HDM2 and that the
PPIs of HDM2 with p53 and E2F-1 are probably
related not only functionally, but also structurally
(Martin et al., 1995; Loughran and La Thangue,
2000; Tortora et al., 2000).
1,4-Benzodiazepine-2,5-diones
1,4-Benzodiazepine-2,5-diones were discovered as
p53–HDM2 antagonists using the so-called
ThermoFluor
 screening method (Pantoliano et al.,
2001) developed by 3-Dimensional Pharmaceuticals
(now Johnson & Johnson). This entails the use of
ﬂuorescent dyes to monitor protein unfolding as a
function of temperature, allowing the detection of test
compounds binding to target proteins. Fluorescence-
based thermal shifts arise as a result of ligand-induced
conformational stabilisation of the assayed protein
and energetic coupling of ligand binding and protein
melting reactions. This method is especially useful to
identify small-molecule modulators of proteins for
which little functional or structural information is
available. Application to HDM2 of this method took
the form of a screen of some 338,000 compounds and
provided 1216 hits, of which 116 originated from a
benzodiazepinedione library (Grasberger et al., 2005).
One of these hits, a racemic benzodiazepinedione
methyl ester (14a), is shown in Fig. 11. A lead opti-
misation programme subsequently established SARs,
including the importance of stereochemistry (Parks et
al., 2005). This provided benzodiazepinedione
carboxylic acid compounds such as 14b and 14c, with
low to sub-micromolar potency in a conventional
p53–HDM2 ﬂuorescence polarisation assay. In this
competitive binding assay a p53-derived 9mer
Fig. 10. Bisaryl-sulfonate and -sulfonamide p53–HDM2 inhibitors 10–13. The binding modes of the lead compounds suggested from the
docking screens were subsequently conﬁrmed using macromolecular NMR methods. It was found that compounds such as 13 did indeed bind
the HDM2 site occupied by the natural p53 ligand (Figure 1).
Antagonists of the p53–HDM2 Interaction 13peptide [N-terminal ﬂuorescein-RFMDYWEGL;
(Bo ¨ ttger et al., 1997)] and an HDM2 fragment
(residues 17–125) were used. Similar to a number of
other p53–HDM2 inhibitor pharmacophores, the
benzodiazepinediones are highly lipophilic (e.g.
CLogP for 14c is 5.9). Hit compounds such as 14a
were carboxylic acid esters. As the carboxylate group
is not directly involved in binding (refer Fig. 11),
solubility could be improved by hydrolysis of the
synthesis precursor esters. The compounds were
prepared using the Ugi four-component condensation
reaction (Gokel et al., 1971) between an anthranilic
acid (R
1 component), an amino acid ester (R
3,4 com-
ponent), an aldehyde (R
2 component), and 1-isocy-
anocyclohexene, followed by acid-catalysed
cyclisation (Hulme et al., 1998). Most of the active
compounds appear to possess an iodo group at C7.
Since aryl iodides can undergo facile in vivo
de-iodination (Goodman et al., 1992), alternative
substituents are desirable. This seems to be possible
and the isopropyl analogue 14e was only marginally
less potent than the corresponding iodo compound
14d.
Isoindolinones
Compounds 15a and 15b (Fig. 12), amongst
others, were discovered by workers at the University
of Newcastle and De Novo Pharmaceuticals as mid-
micromolar potency p53–HDM2 inhibitors in a
biochemical screen, and were subsequently used
as seeds in a structure-guided optimisation strat-
egy (Hardcastle et al., 2005). These compounds
apparently displayed inhibitory activity in the NCI
60 cell-line screen and were COMPARE negative
with respect to any known class of anti-tumour
agents, suggesting a novel mechanism of action
(Paull et al., 1989).
The compounds were docked into the p53-bind-
ing pocket of the published complex structure of
HDM2 (Kussie et al., 1996) using a new hybrid
optimisation method called quantum stochastic tun-
nelling, and implemented in a modelling programme
known as EasyDock (Mancera et al., 2004). A plau-
sible binding mode was proposed and used as the
basis for a subsequent virtual screen of variously
substituted hypothetical isoindolinones. The possible
binding interactions between ligands and receptor
were explored using a simulated annealing optimisa-
tion of an empirical free-energy function using the
programme Skelgen (Stahl et al., 2002). Analogues
able to form at least one additional hydrogen bond
with target residues of HDM2 were selected as virtual
hits and were synthesised and tested. The binding
mode determination was then revisited with the six
most active analogues. This showed that it was
impossible to distinguish a single preferred binding
mode from the many docking solutions. It had pre-
viously been shown that the probability of predicting
an actual binding mode correctly increases signiﬁ-
cantly when multiple binding modes are considered
(Kallblad et al., 2004). Therefore, several high-scor-
ing, unique binding modes were chosen as starting
points for a second round of virtual screening. In
order to validate this approach, some 57 hit com-
pounds, including representatives unique to each
Fig. 11. 3,4-Dihydro-1H-benzo[e][1,4]diazepine-2,5-diones 14 block p53 binding to HDM2 by occupying the hydrophobic pocket normally
recognised by the side chains of p53 residues F19, W23, and L26 (thin sticks) in HDM2-p53 complexes. A view of the binding pose of 14d
(solid sticks) to HDM2 (surface) is shown on the right. Constructed from PDB # 1T4E & 1T4F.
14 Fischerbinding mode, were synthesised and assayed for
inhibition of p53–HDM2 binding using a competitive
p53-binding ELISA format assay with a luminomet-
ric detection end-point. In this assay immobilised
streptavidin was complexed with a biotinylated
p53-derived peptide [biotin-MPRFMDYWEGLN;
(Bo ¨ ttger et al., 1996)]. The peptide Ac-Phe-Met-Aib-
Pmp-(6-Cl-Trp)-Glu-Ac3c-Leu-NH2 served as a
positive control with an IC50 of 5 nM (Garcı´a-Ech-
everrı´a et al., 2000).
This allowed the identiﬁcation of a number of
compounds that displayed improved activity,
including congeners 16a–16d with IC50 values of 14,
18, 5.3, and 16 lM, respectively (Fig. 12). The
increased potency observed for the 4-chlorophenyl
compound 16c was proposed to be consistent with
the predicted binding mode for the parent 16b, which
binds HDM2 with the phenyl ring occupying the Trp
binding pocket, the N-benzylisoindolinone in contact
with the broad, shallow, hydrophobic cleft (F19 site),
and the phenolic OH of the syringic alcohol making a
hydrogen bond to the backbone of Y100 on HDM2.
Modelling suggests that this hydrogen bond from he
Y100 backbone NH is more likely to involve one of
the methoxy groups, however (Fig. 12). It should be
noted that all the isoindolinones were isolated and
tested as racemic mixtures. Providing the proposed
pharmacophore model is correct, one would predict
that the (R)-enantiomers are mainly responsible for
biological activity.
The most potent compound identiﬁed, 16c, was
examined for cellular activity. SJSA cells, in which
the HDM2 gene is ampliﬁed, were treated with
the compounds and cell extracts analysed by
Western immunoblotting for p53 and p21
WAF1.
A dose-dependent increase in HDM2 and p21,
consistent with p53 activation, was observed.
Nutlins
Of all the small-molecule p53–HDM2 anta-
gonists, the nutlins, named geographically after
Hoﬀmann–La Roche’s research site in Nutley, N.J.,
USA, where they were discovered, are the most
advanced, because in vivo proof of concept has been
shown with one of these compounds (Vassilev et al.,
2004). Nutlins are piperazin-1-yl-(2,4,5-triphenyl-4,5-
dihydro-imidazol-1-yl)-methanones 17 (Fig. 13).
Cis-imidazolines were originally identiﬁed as leads in
a high through-put screening campaign and were
subsequently optimised to aﬀord the nutlins. These
compounds displaced recombinant p53 protein from
its complex with HDM2 with IC50 values in the 100–
300 nM range. The imidazoline compounds were
synthesised as racemic mixtures. Enantiomers could
be resolved and it was found that e.g. with 17c, one
enantiomer was 150-fold more potent than the other.
Judging from the complex crystal structure of 17b
with HDM2, the active enantiomers are those with
the 4-(S),5-(R)-imidazoline stereochemistry (Fig. 13;
right panel).
The HDM2-binding modes of nutlin-2 (17b),
determined by X-ray crystallography (Vassilev et al.,
2004), and nutlin-3 (17c), determined by NMR (Fry
et al., 2004), are similar. In both cases one of the
halophenyl rings reaches deeply into the W23 pocket,
while the other occupies the shallower L26 site. In
both cases the alkyloxy substituent at the anisole
ortho position binds into the F19 site, whereas the
piperazine solubilising appendages face away from
Fig. 12. Isoindolinone seed compounds 15 and optimised analogues 16 inhibit the p53–HDM2 interaction. The modelled binding mode,
based on the pharmacophore model presented (Hardcastle et al., 2005), of compound 16c (solid sticks) in the p53 peptide (F19, W23, L26 side
chains shown as thin sticks) binding pocket of HDM2 (surface, from PDB # 1YCR) is shown on the right.
Antagonists of the p53–HDM2 Interaction 15the binding pocket into the solvent (Fig. 13; right
panel).
As far as cellular mode of action is concerned,
treatment with nutlin-1 (17a) of exponentially grow-
ing tumour cell lines with wild-type p53 led to a dose-
dependent increase in the levels HDM2, p53, and
p21
WAF1 proteins, as expected from the release of p53
transcriptional activity. By contrast, cell lines in
which p53 is disabled by mutations or deletions, when
exposed to the same conditions, showed high basal
levels of p53, but no detectable HDM2 or p21. Fur-
thermore, it was shown that accumulation of p53 was
due to decreased degradation of the protein rather
than elevated expression of the p53 gene. Cell cycle
analysis of HDM2-overexpressing cells treated with
nutlin-1 revealed increased G1- and G2-phase frac-
tions and nearly complete depletion of the S-phase
compartment, consistent with induction of the cell-
cycle inhibitor p21. The anti-proliferative potency
of nutlins on tumour cell lines could be clearly
delineated on the basis of p53 status and the possi-
bility that activation of p53 by nutlins was indepen-
dent of their eﬀect on HDM2 was excluded: the
mechanism by which DNA-damaging agents activate
p53 involves phosphorylation of the protein at spe-
ciﬁc serine residues near the HDM2 binding domain.
Of these, S15 is phosphorylated most frequently
(Martinez et al., 1997). Analysis of S15 phosphory-
lation in p53 from lysates of wild-type p53 cells
treated with nutlin-1 and two genotoxic drugs,
doxorubicin and etoposide, revealed that all three
compounds induced accumulation of p53, but only
doxorubicin and etoposide caused phosphorylation
of S15. These results suggested that a genotoxic
mechanism is unlikely to contribute to activation of
p53 by nutlin-1. Next it was demonstrated that the
anti-proliferative eﬀects of nutlins emanate from
induction of apoptosis; co-treatment with caspase
inhibitors reduced cell death, showing the involve-
ment of caspase activation. Perhaps the most exciting
ﬁnding was that human and mouse normal diploid
ﬁbroblasts with a functioning p53 pathway were far
less responsive to nutlins than transformed cell lines.
This selectivity subsequently translated into an
apparent therapeutic margin in a xenograft experi-
ment with the human osteosarcoma cell line SJSA-1,
which over-expresses HDM2. Nutlin-3 was well tol-
erated upon oral administration of 200 mg/kg twice a
day for 20 days and achieved plasma levels above
in vitro IC90. Treatment of mice bearing established
tumours resulted in 90% inhibition of tumour growth
relative to a vehicle-treated control group. The trea-
ted animals did not lose signiﬁcant weight and did
not show any gross abnormalities. By comparison,
doxorubicin administered intravenously at the maxi-
mal tolerated dose inhibited the growth of SJSA-1
xenografts by 81%.
Other Small-Molecule p53–HDM2 Inhibitors
A molecular modelling programme known as
Hydropathic INTeractions (HINT) was originally
used to derive a pharmacophore model that inte-
grated the large body of SAR information from
peptide-based p53–HDM2 inhibition studies (Galatin
and Abraham, 2001). This model (Fig. 14; left panel)
has now been applied as a search query for a 3D
screen of the National Cancer Institute (NCI)
Fig. 13. Nutlins 17 bind in the p53 pocket of HDM2. A complex crystal structure of nutlin-2 (17b; solid sticks) and HDM2 (surface) shows
that all three sub-pockets for the p53 residues F19, W23, and L26 (thin sticks) are occupied by the aryl substituents of the cis-imidazoline core
present in the nutlins. Constructed from PDB # 1RV1.
16 Fischerchemical database (Galatin and Abraham, 2004).
Compounds corresponding to high-ranking hits were
subsequently obtained and screened in a binding
assay based on the p53 peptide
16QETFSDLWKLLP
27
(IC50=13 lM). It was found that most of the
NCI compounds did not demonstrate a dose-depen-
dent inhibition response, with the exception of
the 1,2-diphenyl-3,5-dioxopyrazolidine derivative 18
(Wrzeciono and Szpak-Wojsznis, 1976), for which an
IC50 of 32 lM was measured. Furthermore, at high
concentrations this compound induced p53 tran-
scriptional activity in a reporter gene assay using
the HDM2-overexpressing SJSA-1 osteosarcoma cell
line stably transfected with the ﬁreﬂy luciferase gene
under a p53-dependent promoter (Galatin and
Abraham, 2004).
Finally, the aromatic 6-esters of 5,6-dihydroxy-
bicyclo[2.2.1]heptane-2,3-dicarboxylic acid bis-phenyl-
amide(19a–19e;Figure 14)werereportedasinhibitors
of the p53–HDM2 interaction (Zhao et al., 2002).
Despite modest biochemical potency, e.g. compound
19a was shown to induce apoptotic death of some tu-
mourcells,whichexpresswild-typep53.Similareﬀects
with unidentiﬁed analogues from the same chemical
series have also very recently been reported (Li et al.,
2005).
CONCLUSIONS
The interaction between p53 and HDM2 is one of
the best-understood PPIs in terms of both structure
and inhibitor design. It represents a convincing
example of the current hypothesis that blocking PPI
hot spots with small molecules is an eﬀective way of
modulating protein surface interactions. Several ser-
ies of drug-like small molecules have been discovered
and are currently being optimised. It is hoped that
this work will eventually lead to new mechanism-and
target-speciﬁc cancer drugs.
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